Abiogen acquires EffRx to fortify bone disease portfolio
Pharmaceutical Technology
MAY 30, 2023
The company has developed three bisphosphonates, clodronate, alendronate and Nerixia (neridronate), for the treatment of bone pathologies such as osteoarthritis. Bisphosphonates are drugs that slow the progression of bone loss. EffRx has received several European regulatory approvals for drugs in its portfolio.
Let's personalize your content